PCM
PRAX icon

Prelude Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Prelude Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.92M Sell
9,064
-6,974
-43% -$2.16M 0.22% 110
2025
Q4 		$4.73M Sell
16,038
-12,064
-43% -$2.25M 0.35% 49
2025
Q3 		$1.49M Buy
28,102
+8,202
+41% +$398K 0.12% 225
2025
Q2 		$837K Buy
+19,900
New +$758K 0.08% 301
2023
Q1 		– Sell
-740
Closed -$26.4K – 1405
2022
Q4 		$26.4K Buy
+740
New +$23.1K ﹤0.01% 1166

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Prelude Capital Management's PRAX Position: Q1 2026 in Review

Prelude Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 43% in Q1 2026, selling an estimated $2.16M and leaving 9,064 shares worth $2.92M. The position accounts for 0.22% of the portfolio, ranked #110.

Prelude Capital Management first reported a position in PRAX in Q4 2022 and has held it in 5 quarters since. The position peaked at $4.73M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Prelude Capital Management held 9,064 shares of Praxis Precision Medicines worth $2.92M as of Q1 2026.
  • Prelude Capital Management sold 6,974 Praxis Precision Medicines shares in Q1 2026, an estimated $2.16M.
  • Praxis Precision Medicines made up 0.22% of Prelude Capital Management's portfolio in Q1 2026, its #110 holding.
  • Prelude Capital Management first reported a position in Praxis Precision Medicines in Q4 2022 and has held it in 5 quarters since.
  • Prelude Capital Management's Praxis Precision Medicines position peaked at $4.73M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.